Edition:
United Kingdom

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

94.22USD
4:33pm BST
Change (% chg)

$-3.46 (-3.54%)
Prev Close
$97.68
Open
$97.84
Day's High
$98.08
Day's Low
$94.22
Volume
48,062
Avg. Vol
83,658
52-wk High
$127.74
52-wk Low
$42.51

Latest Key Developments (Source: Significant Developments)

Enanta Pharmaceuticals Reports Q2 Earnings Per Share $0.61
Tuesday, 8 May 2018 

May 8 (Reuters) - Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL SECOND QUARTER ENDED MARCH 31, 2018.Q2 EARNINGS PER SHARE $0.61.Q2 EARNINGS PER SHARE VIEW $0.53 -- THOMSON REUTERS I/B/E/S.ROYALTY REVENUE FOR QUARTER INCREASED TO $44.0 MILLION DUE TO INCREASE IN ABBVIE'S MAVYRET SALES.QTRLY TOTAL REVENUE WAS $44.0 MILLION, COMPARED TO $9.0 MILLION.  Full Article

Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.ENANTA PHARMACEUTICALS INC - PHASE 1 CLINICAL STUDY OF EDP-938 FOR RESPIRATORY SYNCYTIAL VIRUS INITIATED.ENANTA PHARMACEUTICALS INC - PHASE 2 CLINICAL STUDY "INTREPID" OF EDP-305 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS INITIATED.ENANTA PHARMACEUTICALS INC - STRONG CASH BALANCE OF $294M AS OF SEPTEMBER 30, 2017 TO SUPPORT ADVANCING RESEARCH AND DEVELOPMENT PROGRAMS.  Full Article

Enanta Pharma Q4 earnings per share $1.86
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Enanta Pharmaceuticals Inc ::Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017.Q4 earnings per share $1.86.Q4 revenue $75.9 million versus I/B/E/S view $73.1 million.Q4 earnings per share view $2.13 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Enanta Pharmaceuticals Reports Q2 Earnings Per Share $0.61

* ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL SECOND QUARTER ENDED MARCH 31, 2018